Impact of MYCN Status on Response of High-Risk Neuroblastoma to Neoadjuvant Chemotherapy

Journal of Pediatric Surgery - United Kingdom
doi 10.1016/j.jpedsurg.2019.09.067
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

The Targetable Kinase PIM1 Drives ALK Inhibitor Resistance in High-Risk Neuroblastoma Independent of MYCN Status

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2019English

MYCN Controls an Alternative RNA Splicing Program in High-Risk Metastatic Neuroblastoma

Cancer Letters
Cancer ResearchOncology
2016English

Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2018English

Value of TP53 Status for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: A Meta-Analysis

PLoS ONE
Multidisciplinary
2012English

Select BCL-2 Antagonism Restores Chemotherapy Sensitivity in High-Risk Neuroblastoma

BMC Cancer
Cancer ResearchOncologyGenetics
2016English

Impact of Neoadjuvant Chemotherapy on Clinical Risk Scores and Survival in Patients With Colorectal Liver Metastases

Annals of Surgical Oncology
OncologySurgery
2016English

Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer

Journal of Medical – Clinical Research & Reviews
2019English

Molecular Biomarkers to Predict Response to Neoadjuvant Chemotherapy for Bladder Cancer

Cancer Treatment Reviews
MedicineOncologyRadiologyNuclear MedicineImaging
2017English

Epigenetic Regulation of the Neuroblastoma Genes, Arid3b and Mycn

Oncogene
Cancer ResearchGeneticsMolecular Biology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy